Dr. D’Angelo on Future Directions With CAR T-Cell Therapy in Lymphoma
Christopher R. D’Angelo, MD, discusses advances made with CAR T-cell therapy in lymphoma.
Christopher R. D’Angelo, MD, an assistant professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of Nebraska Medical Center, discusses advances made with CAR T-cell therapy in lymphoma.
Recently, it has been possible to achieve durable remissions and complete responses with CAR T-cell therapy in this patient population, D’Angelo says. This could indicate that this modality may represent a potential curable approach for a refractory population, according to D’Angelo.
Safer CAR T-cell products with increased efficacy and complete, durable responses, are anticipated, D'Angelo notes.
Additionally, the emergence of novel CAR T-cell therapy combinations with agents such as lenalidomide (Revlimid) and ibrutinib (Imbruvica), possess potential, D’Angelo concludes.
